Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and

Lars Wortmann1, Nico Bräuer1, Simon J Holton1

  • 1Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.